|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM020572573 |
| 003 |
DE-627 |
| 005 |
20250125092913.0 |
| 007 |
tu |
| 008 |
231221s1990 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0069.xml
|
| 035 |
|
|
|a (DE-627)NLM020572573
|
| 035 |
|
|
|a (NLM)2075879
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Yushita, Y
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Induction therapy with CDDP and ADM for stage D prostatic cancer and its clinical response
|
| 264 |
|
1 |
|c 1990
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.04.1991
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a From September 1983 to September 1989, 20 patients with newly diagnosed stage D prostatic cancer were treated with cis-platinum (CDDP) and adriamycin (ADM) as the induction therapy. Analysis of histological and clinical effects on the induction therapy revealed partial response (PR) in 13 cases and no change (NC) in 7 cases according to Shimazaki's response criteria, and PR in 4 cases, NC in 15 cases and progression (PD) in 1 case according to NPCP criteria. Histological Ef 0-b effect was found in 2 cases, Ef 1 in 7 cases, Ef 2 in 3 cases, Ef 3 in 2 cases and Ef 4 in 2 cases. Analysis of long-term results revealed relapse in 9 cases and cancer death in 6 cases. The 1-year, 3-year and 5-year continued response rates for all cases were 85.7, 40.2 and 32.1%, respectively. The 1-year, 3-year and 5-year survival rates were 100, 64.3 and 53.6% respectively. Histologically, low responsive cases showed a tendency of relapse and cancer death more frequently than high responsive cases. These results suggest that CDDP and ADM therapy is more effective than hormone therapy in newly diagnosed stage D prostatic cancer as an induction therapy
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 700 |
1 |
|
|a Sakai, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nomata, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Suzu, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Minami, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ogawa, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamashita, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kanetake, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Saito, Y
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 36(1990), 12 vom: 15. Dez., Seite 1415-21
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:1990
|g number:12
|g day:15
|g month:12
|g pages:1415-21
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 1990
|e 12
|b 15
|c 12
|h 1415-21
|